Dominari Holdings

Dominari Holdings owns a controlling interest in Dominari Securities LLC, a FINRA-registered broker-dealer. The subsidiary provides investment banking, advisory, and capital-raising services. This ownership structure allows the parent company to underwrite securities for its own portfolio entities, a vertically integrated arrangement that is unusual for a firm of Dominari's size.

When the company operated as AIkido Pharma, it built a portfolio of early-stage drug-discovery assets, some licensed from university labs. Under CEO Kyle Wool, the firm systematically reduced those legacy positions, restructuring around the Dominari brand. Any remaining biotech assets are now held alongside the financial-services business, though the firm has not disclosed specific ongoing clinical programs in recent regulatory filings.

No. Dominari Holdings is a publicly traded company listed on the Nasdaq under the ticker DOMH. It functions as a holding company with operating subsidiaries, not as a single-family or multi-family office. Its capital comes from public equity markets rather than a private family's wealth.

Dominari Acquisition Corp. is a special purpose acquisition company sponsored by Dominari Holdings, targeting a business combination in biotechnology or related sectors. The SPAC gives the firm a pathway to take a private company public while earning sponsor economics. Because Dominari Securities can also advise on such transactions, the SPAC creates a potential pipeline for the broker-dealer's advisory business.

CEO Kyle Wool and CIO Anthony Hayes are the named principals on Dominari's public filings. Wool has driven the firm's strategic shift from pure biotech incubation to a diversified holding company with a financial-services arm. The firm has not disclosed an investment committee or additional decision-makers beyond its executive team.